Resultats de la cerca - Larry Alphs

  • Mostrar 1 - 13 resultats de 13
Refinar resultats
  1. 1
    Treatment of Negative Symptoms

    Treatment of Negative Symptoms per William T. Carpenter, Douglas W Heinrichs, Larry Alphs

    Publicat 1985
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

    Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? per Larry Alphs, Fabrizio Benedetti, W. Wolfgang Fleischhacker, John M. Kane

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study

    Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory a... per H. Lynn Starr, Jason Bermak, Lian Mao, Steve Rodriguez, Larry Alphs

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

    Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, dou... per Larry Alphs, Cynthia A. Bossie, Jennifer Kern Sliwa, Yi-Wen Ma, Norris Turner

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    The Challenge of Offering Long-Acting Antipsychotic Therapies

    The Challenge of Offering Long-Acting Antipsychotic Therapies per Peter J. Weiden, Rebecca S. Roma, Dawn I. Velligan, Larry Alphs, Matthew DiChiara, Brad Davidson

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Methodological Issues in Negative Symptom Trials

    Methodological Issues in Negative Symptom Trials per Stephen R. Marder, David G. Daniel, Larry Alphs, A. George Awad, Richard S.E. Keefe

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia

    Real-World Outcomes of Paliperidone Palmitate Compared to Daily Oral Antipsychotic Therapy in Schizophrenia per Larry Alphs, Carmela Benson, Kimberly Cheshire-Kinney, Jean‐Pierre Lindenmayer, Lian Mao, Stephen C. Rodriguez, H. Lynn Starr

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    A randomized, double‐blind, placebo‐controlled study of maintenance treatment with adjunctive risperidone long‐acting therapy in patients with bipolar I disorder who relapse frequently

    A randomized, double‐blind, placebo‐controlled study of maintenance treatment with adjunctive risperidone long‐acting therapy in patients with bipolar I disorder who relapse freque... per Wayne Macfadden, Larry Alphs, J. Thomas Haskins, Norris Turner, Ibrahim Turkoz, Cynthia A. Bossie, Mary J. Kujawa, Ramy Mahmoud

    Publicat 2009
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Genome-wide association study of paliperidone efficacy

    Genome-wide association study of paliperidone efficacy per Qingqin S. Li, Nathan E. Wineinger, Dong‐Jing Fu, Ondrej Libiger, Larry Alphs, Adam Savitz, Srihari Gopal, Nadine Cohen, Nicholas J. Schork

    Publicat 2016
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression

    Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression per Ibrahim Turkoz, Larry Alphs, Jaskaran Singh, Carol Jamieson, Ella Daly, M. Shawi, John J. Sheehan, Madhukar H. Trivedi, A. John Rush

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

    Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffe... per Dong‐Jing Fu, Ibrahim Turkoz, Richard Bruce Simonson, David P. Walling, Nina R. Schooler, Jean‐Pierre Lindenmayer, Carla M. Canuso, Larry Alphs

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

    Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind,... per Carla M. Canuso, Jaskaran Singh, Maggie Fedgchin, Larry Alphs, Rosanne Lane, Pilar Lim, Christine Pinter, David Hough, Gerard Sanacora, Husseini K. Manji, Wayne C. Drevets

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?

    What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It? per Aaron S. Kemp, Nina R. Schooler, Amir H Kalali, Larry Alphs, R. Anand, George Awad, Michael Davidson, Sanjay Dubé, Larry Ereshefsky, Georges M. Gharabawi, Andrew C. Leon, J.P. Lépine, Steven G. Potkin, An Vermeulen

    Publicat 2008
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: